Latest HBV Stories
Among known risk factors for hepatocellular cancer, smoking, obesity, and heavy alcohol consumption, along with chronic hepatitis B and C infection, contribute to a large share of the disease burden in Europe.
JOHANNESBURG, July 25, 2011 /PRNewswire/ -- The South African National Blood Service (SANBS) presented new data which demonstrated that its use of Novartis nucleic acid testing (NAT) products to screen donated blood for HIV and Hepatitis has resulted in a significant increase in the safety of the South African blood supply.
According to new research at Columbia Presbyterian Medical Center, high rates of chronic hepatitis B infection (HBV) are found in pregnant minority and immigrant women in the New York City area, and most of them do not receive education, appropriate follow-up testing or referral, which is considered the standard of care for all persons newly identified as HBV carriers.
Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.
BOSTON, Nov. 1, 2010 /PRNewswire/ -- Researchers studied the treatment of pregnant women with hepatitis B virus (HBV) with Telbivudine in their second to third trimesters.
Panel calls for a conservative approach until more clinical data and therapeutic options are available DOYLESTOWN, Pa., Oct.
GERMANTOWN, Maryland and DES PLAINES, Illinois, October 12, 2010 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Abbott (ABT: NYSE) today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed. Under the terms of the agreements, QIAGEN will receive kits for a PCR-based molecular assay...
PLEASANTON, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Roche Molecular Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food & Drug Administration (FDA) has approved the COBASÂ® AmpliPrep / COBASÂ® TaqManÂ® HBV Test v2.0 for use in the United States.
WASHINGTON, DOYLESTOWN, Penn., and SAN FRANCISCO, Sept. 14 /PRNewswire/ -- The U.S.